Ibrutinib, an oral BTK inhibitor taken once daily, is the only targeted treatment to show improved progression-free survival (PFS). Venetoclax is a single agent or combination with rituximab or obinutuzumab for treating CLL and SLL. It is an oral inhibitor of the anti-apoptotic protein BCL-2. In 16% of treated patients with relapsed and refractory CLL, […]